Details of the Drug | DrugMAP

General Information of Drug (ID: DMGJR0Y)

Drug Name

VB-201

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Phase 2	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C29H60NO8P
Canonical SMILES: CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O
InChI: 1S/C29H60NO8P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-19-23-35-26-28(36-24-20-18-21-29(31)32)27-38-39(33,34)37-25-22-30(2,3)4/h28H,5-27H2,1-4H3,(H-,31,32,33,34)/t28-/m1/s1
InChIKey: JGGNOCUEWOGWPL-MUUNZHRXSA-N

Cross-matching ID

PubChem CID: 45138527
CAS Number: 630112-41-3
TTD ID: D0N2IE

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37.
2	ClinicalTrials.gov (NCT01001468) Study to Assess VB-201 in Patients With Psoriasis. U.S. National Institutes of Health.